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Objective: Malperfusion syndrome is a known predictor of poor outcomes in acute type B dissection. We describe our
experience with revascularization in the acute setting.
Methods: Patients undergoing intervention for ischemia complicated acute type B dissection between November 1999 and
March 2011 were reviewed. Details of presenting condition, surgical intervention, and postoperative course were
collected. Descriptive and inferential statistical analyses included survival and freedom from reintervention using Cox
proportional hazards models.
Results: A total of 61 patients were identiﬁed with malperfusion in at least one territory, including spinal cord 7/61 (12%),
mesenteric 37/61 (61%), renal 45/61 (73%), and lower extremity 38/61 (62%). Thoracic stent grafts were placed in all
patients, and 41% of patients required adjunctive branch vessel stenting. After intervention, resolution of the ischemia was
reported in 57/61 (93%) of patients. The 30-day/in-hospital mortality was 21.3%. The 6-month, 1-year, and 5-year
survival was 75% (95% CI, 65%-87%), 71% (95% CI, 61%-84%), and 56% (95% CI, 43%-74%), respectively. The 6-
month, 1-year, and 5-year freedom from reintervention was 84% (95% CI, 75%-95%), 76% (95% CI, 65%-90%), and
42% (95% CI, 24%-76%), respectively. Territory of ischemia was not independently associated with mortality, but place-
ment of a stent graft proximal to the subclavian artery was associated with poor outcome hazard ratio 2.91 (95% CI, 1.09-
8.11; P [ .034).
Conclusions: Malperfusion in any territory at the time of presentation in patients with type B dissections can be treated
with endovascular intervention with acceptable outcomes. Opposed to branch vessel intervention alone, increased aortic
intervention with regard to proximal coverage may signify more serious disease is associated with worse outcome. (J Vasc
Surg 2013;57:1283-90.)5Ischemia caused by acute type B aortic dissection
(ABAD) is a life-threatening medical emergency and occurs
in approximately 15% to 42% of all ABAD patients.1-3 Mal-
perfusion caused by either a dynamic or static obstruction
to the renal, mesenteric, spinal, or iliac arteries demands
surgical intervention if the end organs are threatened. In
cases where the organs are not threatened, and if there is
no concern for acute aneurysm degeneration and rupture,
medical therapy with aggressive antihypertensive and anti-
impulse therapy are the mainstay therapies.4 Two mecha-
nisms have been accepted as the primary causes of ischemia
following aortic dissection: (1) true lumen collapse in either
a complete or transient manner and (2) extension of the
dissection into visceral arteries causing branch vesselthe Heart and Vascular Institute, The Cleveland Clinic.
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://dx.doi.org/10.1016/j.jvs.2012.10.101obstruction. Failure to treat such malperfusion syndromes
caused by complicated ABAD (cABAD) results in a >50%
chance of death for affected patients.1,5
Several emergency surgical options exist to treat
cABAD with open surgical aortic graft replacement and
thoracic endovascular aortic repair (TEVAR), being the
twomain treatment options, whereas others have advocated
fenestration.6 Open surgical repair in these emergent cases
has been associated with high morbidity and mortality.1,7
Since Dake ﬁrst reported on the use of TEVAR for aortic
dissection,5 it has become accepted as an effective treatment
for ABAD.3,5,7-13 This procedure seeks to seal the entry
tear, stent open the true lumen, and if possible, completely
occlude the false lumen in a proximal to distal fashion. A
growing body of knowledge has advocated TEVAR as the
preferred treatment method for emergency ABAD treat-
ment, and accordingly, open surgical correction of malper-
fusion is now rarely performed.7,9-12
Data concerning the outcomes of TEVAR for ABAD
complicated by ischemia (icABAD) are limited to small
subsets of most study populations or by short-term
follow-up.12 This study aimed to assess overall survival
and effectiveness of patients who received TEVAR for
icABAD, with speciﬁc attention to those patients suffering
from visceral malperfusion
METHODS
Patient selection. A retrospective chart review assessed
all patients who had malperfusion resulting from Stanford
type B aortic dissection. All patients who ﬁt this criterion1283
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vessels between November 1999 and March 2011 were
screened for inclusion. Study data were collected from
medical records and managed using Research Electronic
Data Capture (REDCap) electronic data capture tools
hosted at Cleveland Clinic.14 Information on 87 clinical
variables was recorded concerning patient demographics
and comorbidities, dissection extent, operative variables,
aortic branch vessel involvement, and outcome measures.
Acute type B dissection was deﬁned as a spontaneous,
nontraumatic dissection involving the descending aorta that
was diagnosed within 14 days of onset of symptoms.15 Diag-
nosis of ABAD was based on the preoperative computerized
axial tomography (CAT) scan. In general, the diagnosis of
malperfusion in the context of ABAD was based on the
patient’s presenting symptoms in addition to computerized
tomography conﬁrmation and intraoperative visualization of
obstruction to any aortic branch vessels. The categorization
of presenting symptoms has been described by White et al7
and includes (1) visceral hypoperfusion (acute abdomen,
greater-than-expected abdominal pain based on physical
examination ﬁndings, lactic acidosis, or requirement for
bowel resection); (2) renal hypoperfusion (oliguria/anuria
with rising blood creatinine and blood urea nitrogen levels);
(3) lower extremity hypoperfusion (abnormal pulse examina-
tion associated with ischemic rest pain, off-pallor, paresthesia,
or paralysis); and (4) spinal cord hypoperfusion (altered
motor function in unilateral or bilateral lower extremities
attributed to central nervous system dysfunction). All patients
in extremis were offered repair or had a repair attempt made
depending on admitted condition.
Exclusion criteria included type A dissection, open
aortic graft replacement, traumatic dissection, and treat-
ment for dissection at an outside hospital prior to transfer.
Sixty-one patients were identiﬁed for inclusion based on
these criteria. All patients underwent TEVAR. Subsequent
to the primary analysis, three additional patients were iden-
tiﬁed who had only branch vessel stenting alone in the face
of acute type B dissection and were excluded from initial
analysis. Inclusion of these patients did not change the
outcome of the study.
Variable deﬁnitions. All variables were reported based
on standards established by the Society of Vascular Surgery
Ad Hoc Committee on Reporting Standards for TEVAR.16
All dissections included in this study were spontaneous
with or without connective tissue disorders. Blood pressure
control was gathered from preoperative in-ofﬁce visits.
Hypertension was determined from prior medical records.
Tight blood pressure control was deﬁned as constant
management of systolic blood pressure#130.Uncontrolled
hypertension was deﬁned as two or more incidences of
systolic blood pressure >130 during clinical visits or based
on the attending physician’s report. Pulmonary complica-
tion was deﬁned as an inability to be weaned from a venti-
lator >24 hours postoperatively. Aortic diameter was
measured perpendicular to theminor axis at the widest point
recorded. Time to treatment represents the difference
between procedure start time and time of admission.Endovascular procedure. The procedure generally
involved three-vessel access, with open surgical right
common femoral artery exposure, and left common femoral
and left brachial percutaneous access. This approach was
preferred because the wire and catheter provide graft
placement landmarks for tears adjacent to the subclavian
artery. In most cases, intravascular ultrasound was used in
conjunction with conventional angiography to assist and
conﬁrm access was in the true lumen. Entry tear identiﬁca-
tion was attempted using intravascular ultrasound, but rapid
restoration of perfusion was the primary goal. The aim of the
thoracic stent graft placement was to seal the entry tear and
expand the true lumen. The length of vessel treated was at
the discretion of the surgeon, with above goals taken into
consideration. No bare-metal components were implanted.
Adjunctive branch vessel stenting was done to assist their
true lumen expansion in the face of compromised ﬂow
because of extension of the ﬂap into the vessel.
Statistical methods. De-identiﬁed data were imported
from REDCap to SAS (SAS Institute, Cary, NC). Summa-
ries of the entire cohort were created using medians and
ranges for continuous measures and frequencies and
percentages for categorical measures. This was done to
identify any out-of-range values. Kaplan-Meier estimates
of survival and freedom from reintervention were calcu-
lated along with 95% conﬁdence intervals (CIs). Cox
proportional hazard regression models were also ﬁt, and
hazard ratios from these models were used to estimate the
risk of death or reintervention. Analyses were performed
using SAS software (v. 9.2; SAS Institute).
RESULTS
Patient demographics. Patient demographics are listed
in Table I. The presenting symptoms of ischemia were
a prerequisite for study inclusion and were present in at least
one vascular bed for all 61 patients. Fifty-four of the 61
patients (88.5%) analyzed had visceral ischemia (renal
or mesenteric). Forty-three (70.5%) patients had more than
or equal to two affected vascular beds, whereas 16 (26.2%)
had more than or equal to three affected vascular beds.
Ischemia was categorized by vascular bed affected and
analyzed for survival estimates.
The 30-day/in-hospital mortality rate was 21.3% (13
patients). Intraoperative angiography showed ischemia
resolution in 57 patients (93.4%). Two patients with unre-
solved restoration of ﬂow (50%) died 1 day postoperatively
because of unresolved mesenteric ischemia causing bowel
death, whereas the other two were successfully discharged
and were alive at the conclusion of this study. Cumulative
survival at 6 months, 1, 3, and 5 years was 75% (95% CI,
65%-87%), 71% (95% CI, 61%-84%), 60% (95% CI, 47%-
76%), and 56% (95% CI, 43%-74%), respectively (Fig 1).
Univariable factors associated with survival for demo-
graphics are listed in Table I. Men (hazard ratio [HR],
0.42; 95% CI, 0.18-0.96; P ¼ .04) and nonsmoking status
(HR, 0.31; 95% CI, 0.10-0.99; P ¼ .047), were associated
with improved survival, while acute and chronic renal
failure (HR, 2.30; 95% CI, 0.90-5.88; P ¼ .083) trended
Table I. Univariate analysis for cumulative survival
Demographic
variable
Number (%) or
median (SD) HR (95% CI) P
Male sex 44 (72.1) 0.42 (0.18-0.96) .04
Quit smoking 21 (34.4) 0.31 (0.10-0.99) .047
Obesity 26 (42.6) 1.31 (0.56-3.04) .53
Hypertension 57 (93.4) 0.35 (0.10-1.20) .096
Renal issues 9 (14.8) 2.30 (0.90-5.88) .083
Heart disease 19 (31.1) 1.21 (0.50-2.89) .67
Diabetes 15 (24.6) 1.22 (0.48-3.13) .67
Previous aortic operation 10 (16.4) 0.62 (0.18-2.11) .44
COPD 11 (18.0) 1.58 (0.58-4.32) .37
Connective tissue disorder 6 (9.8) 0.31 (0.04-2.36) .26
Continuous variable P > c2
Age 1.02 (0.99-1.05) .30
BMI 1.00 (0.94-1.06) .98
Max aortic diameter 0.98 (0.94-1.02) .29
Preoperative variable P
Lower extremity ischemia 38 (62.3) 0.54 (0.23-1.25) .15
Spinal cord ischemia 7 (11.5) 2.13 (0.71-6.37) .17
Mesenteric ischemia 37 (60.7) 1.82 (0.71-4.65) .21
Renal ischemia 45 (73.8) 1.64 (0.56-4.87) .37
Visceral ischemia 53 (86.9) 3.59 (0.48-26.7) .21
Preop thrombosed FL 15 (24.6) 1.00 (0.39-2.56) .99
Operative variable
Time to treatment
>24 hours
25 (41.0) 0.85 (0.36-2.00) .72
Stent type
Gorea 38 (62.3) - -
Zenith 21 (34.4) 1.32 (0.54-3.24) .55
LSA occlusion 37 (60.6) 2.97 (1.09-8.11) .034
Carotid-LSA bypass 8 (13.1) 0.77 (0.18-3.32) .72
Branch vessel stenting 25 (41.0) 0.92 (0.39-2.15) .84
Partial FL thrombosis 8 (19.0) 4.48 (0.45-44.7) .20
BMI, Body mass index; CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; FL, false lumen; HR, hazard ratio; LSA, left subclavian
artery; SD, standard deviation.
Bold entries indicate statistical signiﬁcance.
aReference value for Zenith stents.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 5 Ryan et al 1285toward decreased survival. Surprisingly, hypertension
(HR, 0.35; 95% CI, 0.10-1.20; P ¼ .096) trended toward
increased survival at all time points, but both renal failure
and hypertension were not statistically signiﬁcant (.05 <
P < .10) for their respective associations with survival. It
is worth noting that seven of nine patients who underwent
TEVAR for icABAD with preoperative renal issues were
dialysis dependent for the remainder of their follow-up
period and four of these seven died #30 days.
Univariate analyses to determine if survival was associ-
ated with preoperative ischemic factors were performed
(Table I). No one type of ischemia was associated with
decreased survival: spinal (HR, 2.13; 95% CI, 0.71-6.37;
P ¼ .17), lower extremity (HR, 0.54; 95% CI, 0.23-
1.25; P ¼ .15), mesenteric (HR, 1.82; 95% CI, 0.71-
4.65; P ¼ .21), and renal (HR, 1.64; 95% CI, 0.56-4.87;
P ¼ .37). When compared with patients suffering lower
extremity ischemia alone, patients suffering visceral
ischemia showed no signiﬁcant differences in cumulativesurvival at 6 months or 1, 3, and 5 years (Fig 1). There
appeared to be a trend associating visceral ischemia with
decreased long-term survival, but the associated P value
was .21 rendering this ﬁnding insigniﬁcant.
Operative variables. Comparative data based on
surgical demographic factors are presented in Table I.
Median time to treatment was 60.3 6 97.4 hours. Because
of the large SD, patients were grouped depending on
whether they had received treatment within 24 hours or
beyond 24 hours. Treatment time >24 hours (HR, 0.85;
95% CI, 0.36-2.00; P ¼ .72) and stent type (Zenith stent
(Cook Medical, Bloomington, Ind) (HR, 1.32; 95% CI,
0.54-3.24; P ¼ .55) were not associated with diminished
survival at 12, 36, or 60months. No length of the stent graft
was bare metal, as Zenith stents used between 1999 and
2004 were constructed intraoperatively. The proximal
landing zone in reference to the left subclavian artery (LSA)
was distal for 24 patients (39.3%), partially occluding in 10
patients (16.4%), and proximal in 27 patients (44.3%).
Partial or complete coverage of the LSA was negatively
associated with survival (HR, 2.97; 95% CI, 1.09-8.11; P ¼
.034). Although achieving at least 2 cm of proximal seal was
not feasible in this emergent patient population, all efforts to
maximize landing zone proximal to the primary entry tear
were taken.
Branch vessel stenting was carried out in 25 patients
(41%). The celiac and superior mesenteric arteries had
bare metal stents deployed in one (1.6%) and six (9.8%)
patients, respectively. Seventeen renal arteries were stented
in 13 patients (21.3%). Iliac artery stenting was performed
19 times in 13 patients (21.3%). One patient had the LSA
stented, and three patients (4.9%) had the left common
carotid stented. These stents acted as chimneys when aortic
grafts jumped proximally upon deployment. Branch vessel
stenting (HR, 0.92; 95% CI, 0.39-2.15; P ¼ .84) was not
associated with survival.
Preoperative false lumen status was also assessed. Upon
admission, 46 patients (75.4%) had a patent false lumen,
whereas 15 (24.6%) had either partial or complete throm-
bosis of the false lumen. This variable had no association
with survival (HR, 1.00; P ¼ .99). Primary intimal entry
tear was successfully occluded in 60 patients (98.4%).
One patient suffered cardiac arrest intraoperatively
following deployment of a stent graft with a small type
IA endoleak. Although the patient was resuscitated, the
endoleak was not repaired, as the patient succumbed to
severe metabolic acidosis secondary to bowel infarction
within 12 hours of the procedure.
Postoperative false lumen status was recorded at the
last follow-up date for each patient. Mean follow-up time
was 37.1 6 30.4 months. Eight patients (13.1%) had
partial thrombosis of the false lumen following TEVAR,
whereas eight (13.1%) achieved complete thrombosis.
Twenty-ﬁve patients (40.9%) had complete thrombosis of
the false lumen along the length of the stent graft but
had a distal reentry tear that gave rise to a distal, patent
false lumen. Because of either early mortality or lack of
Fig 1. Kaplan-Meier estimates for cumulative survival.
Table II. Complications following TEVAR for icABAD
Variable No. (%)
Acute renal failure 41 (67.2)
Transient dialysis 7 (17.1)
Permanent dialysis 15 (36.6)
Pulmonary failure 27 (44.3)
Tracheotomy requirement 11 (40.7)
Late aortic event No. (%)
Reintervention frequency,
No. (%)
Retrograde extension 2 (3.3) 1 (50.0)
Aneurysmal degeneration 7 (11.5) 8 (57.1)
Type I endoleak 7 (11.5) 4 (57.1)
Type II endoleak 4 (6.6) 3 (75.0)
Type III endoleak 1 (1.6) 1 (100)
Aortic rupture 0 (0.0) –
icABAD, Acute type B aortic dissection complicated by ischemia; TEVAR,
thoracic endovascular aneurysm repair.
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assessed for postoperative false lumen status.
Complications. Table II outlines complications fol-
lowing TEVAR for icABAD. For the entire cohort, the
median postoperative creatinine level was 2.50 6 0.72
mg/dL. Three patients (4.9%) suffered a stroke post-
operatively. Two of these patients diedwithin 3weeks of their
TEVAR procedures, whereas the third died within 3months.
Late aortic events anytime during follow-up were preva-
lent in this complicated group with 25 patients (41%) expe-
riencing at least one aortic-related complication. Novel
aneurysm development occurred in seven patients (11.5%),
with ﬁve of these patients requiring reintervention (71.4%).
Retrograde dissection occurred in two patients (6.6%) withone requiring open surgical aortic graft repair of the
ascending aorta. The second patient suffered retrograde
dissection with concurrent multiple organ failure. His
critical condition precluded ascending aortic graft replace-
ment and he subsequently died 17 days postoperatively.
Endoleaks were observed in 12 patients during follow-up.
False lumen status at the time of reported endoleaks
was recorded. Of those suffering type I endoleaks, three
were not assessed because of early mortality, three had
partial false lumen thrombosis, and one had a patent false
lumen because of the endoleak. All four of the seven
(57.1%) affected by type I endoleak who survived the initial
dissection underwent a reintervention operation. All type II
endoleak patients had partial thrombosis as a result of their
endoleaks, and three of four affected by type II endo-
leak had reinterventions performed. The single patient who
had a type III endoleak suffered from Ehlers-Danlos
syndrome and presented with mesenteric ischemia. The
graft was placed emergently, but because of the friability of
this patient’s aorta, dilation occurred requiring open graft
replacement. No further reinterventions were required
during 3-year follow-up. Kaplan-Meier estimates for free-
dom from reintervention for the entire cohort were calcu-
lated and are presented in Fig 2. Percentage estimates for
6, 12, 36, and 60 months were 84% (95% CI, 75%-95%),
76% (95% CI, 65%-90%), 68% (95% CI, 53%-86%), and
42% (95% CI, 24%-76%), respectively.
Univariable analysis was carried out for patient demo-
graphic and surgical demographic factors for freedom from
reintervention (Table III). Those who quit smoking preoper-
atively had a signiﬁcant increase in freedom from reinterven-
tion (HR, 0.23; 95% CI, 0.07-0.74; P ¼ .014). In addition,
nonsmokers had a strong trend toward avoidance of
Fig 2. Kaplan-Meier estimates for cumulative freedom from reintervention.
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statistical signiﬁcance (HR, 0.23; 95% CI, 0.05-1.05; P ¼
.058). Spinal cord ischemia was identiﬁed as a signiﬁcant risk
factor for reintervention (HR, 5.39; 95% CI, 1.35-21.6; P
¼ .017).All patientswhoexperienced ischemia to this vascular
bed required reintervention within 1-year post-TEVAR.
Branch vessel stenting was also negatively associated with
freedom from reintervention (HR, 4.33; 95% CI, 1.39-
13.5;P¼ .012).When comparing thosewith lower extremity
ischemia alone with those with visceral ischemic involvement,
no signiﬁcant difference was found for freedom from reinter-
vention (HR, 0.97; 95% CI, 0.27-3.47; P ¼ .97).DISCUSSION
The ﬁrst report of treating ischemia-complicated acute
type B aortic dissection using endovascular stent grafts was
in 1999 by Dake et al.5 Since this initial report, many
studies have postulated that TEVAR for icABAD may be
superior to open surgical aortic graft replacement in terms
of increased short-term and overall survival, but few have
separated ischemia cABAD patients from the larger pool
of patients with cABAD. Therefore, the purpose of this
study was to determine survival and freedom from reinter-
vention outcomes for this speciﬁc cohort.
Speciﬁc variables were predictive for survival in our
cohort. Women had a signiﬁcant association with decreased
30-day survival. Nienaber et al have examined this gender-
related difference in survival previously.17 They reported
that women had a signiﬁcantly decreased survival rate
because of later presentation and older age. Nienaber
et al also cited a trend toward greater time to treatment
as being a likely negative factor. Nonsmoking status was
also associated with increased survival in our cohort. Thisis not surprising, as the toxic effects of tobacco smoking
on the vasculature are well established.18
Paradoxically, hypertensive patients trended toward
having an increased cumulative survival. It is possible that
high blood pressure could be protective after the onset of
ischemia to deliver intermittent ﬂow to malperfused vascular
beds until anti-impulse therapy was started. Preoperative
renal insufﬁciency and failure, whether acute or chronic,
also trended toward decreased survival. Acute renal failure
has been shown to signiﬁcantly increase early mortality for
in-hospital patients and has also been associated with respi-
ratory failure.19 Along with renal ischemia that was concur-
rent in eight of the nine patients with preoperative renal
problems, there was a large increase in early mortality risk
imparted by the combination of these disorders.
Left subclavian artery occlusion by the TEVAR graft
was an independent predictor of decreased survival in this
cohort. Recent research has shown trends in higher rates
of cerebrovascular accident in patients with LSA occlusion,
and two of our three stroke patients had a proximal landing
zone proximal to the LSA.20 These ﬁndings are substanti-
ated by the Study of Thoracic Aortic Type B Dissection
Using Endoluminal Repair (STABLE) trial in which all
patients who suffered strokes had LSA coverage.21 The
need to cover the LSA with a thoracic stent graft to occlude
the primary entry tear indicates the severity of aortic disease
present, which could also contribute to the early mortality
of the patient.
Our in-hospital/30-day mortality rate of 21.3% was
higher compared with results described in multiple
contemporary studies examining TEVAR for malperfusion
caused by type B dissection.8,9,11,22 Speciﬁcally, Conrad
et al reported 12% 30-day mortality in a 33-patient
cohort,23 O’Donnell et al reported 30-day mortality of
Table III. Univariate analyses for freedom from
reintervention
Variable HR (95% CI) P
Male 1.39 (0.39-4.93) .61
Nonsmoker 0.23 (0.05-1.05) .058
Quit smoking 0.23 (0.07-0.74) .014
Obesity 0.64 (0.22-1.84) .41
Hypertension n/a n/a
Preop renal issues 1.11 (0.25-5.02) .89
Diabetes 0.48 (0.13-1.76) .27
Previous aortic operation 1.66 (0.53-5.15) .38
COPD 0.41 (0.05-3.17) .39
Connective tissue disorder 1.22 (0.33-4.58) .77
Continuous variable P > c2
Age 1.00 (0.96-1.03) .75
BMI 1.01 (0.95-1.07) .83
Max aortic diameter 0.99 (0.94-1.03) .50
Preoperative variable P
Lower extremity ischemia 0.50 (0.18-1.38) .18
Spinal cord ischemia 5.39 (1.35-21.59) .017
Mesenteric ischemia 1.72 (0.60-4.97) .31
Renal ischemia 1.60 (0.50-5.16) .43
Thrombosed FL 1.50 (0.52-4.36) .45
Operative variable
Time to treatment
>24 hours 1.08 (0.40-2.93) .88
Stent type
Zenitha 1.05 (0.32-3.48) .94
LSA occlusion 0.77 (0.28-2.11) .61
Carotid-LSA bypass 1.87 (0.51-6.83) .34
Branch vessel stenting 4.33 (1.39-13.5) .012
Partial FL thrombosis 3.16 (0.55-18.3) .20
BMI, Body mass index; CI, conﬁdence interval; COPD, chronic obstructive
pulmonary disease; FL, false lumen; HR, hazard ratio; LSA, left subclavian
artery.
Bold entries indicate statistical signiﬁcance.
aGore stent as reference value (HR, 1.00).
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a conglomerate study mortality of 10.8%.7 The differences
in survival may be the patient acuity, as all of the patients in
our study presented with severe end-organ ischemia and
emergent operative indications. In 36 patients (59.0%),
these indications prompted emergent TEVAR less than
24 hours after admission with three (4.9%) receiving dial-
ysis in the operating room. Reperfusion was successful in
57 patients (93.4%), which suggests that ischemic damage
in many patients in the 30-day mortality cohort had
advanced beyond repair by the time treatment could be
initiated. Of the 13 patients who died within 30 days of
treatment, seven succumbed to either multiple organ
failure or reperfusion injury because of ischemia. Malperfu-
sion as a result of ABAD is known to be a risk factor for
high morbidity and mortality in the already-high-risk
ABAD patient population, but treatment with open
surgery has been reported to have a 30-day mortality
ranging from 30.8% to 88% for patients presenting
with mesenteric ischemia.22,25 Although we did not ﬁnd
any signiﬁcant difference in survival or freedom fromreintervention between those treated before or after 24
hours, delays in treating an ischemic condition undoubt-
edly cause irreversible damage.
Actuarial survival at 1, 3, and 5 years was 71%, 60%,
and 56%, respectively. The 1-year survival rate of
the present study was within the range of contemporary
studies done on cABAD patients with very few studies
having performed actuarial analysis to 5 years with a cABAD
cohort.22 Verhoye et al reported no late deaths in a cohort
of 16 patients at 5 years. Compared with our cohort
however, only 50% suffered malperfused branch arteries
in their study.9 Necrosis attributable to ischemia was the
cause of death in seven of 13 patients (54%) in our
30-day mortality cohort, which underlines the limitations
of any treatment method for icABAD. Delays in diagnosis
or transfer to a hospital equipped to treat these patients can
be the difference between life and death.27 Because most
patients in the study were transferred from an outside
hospital, determining diagnosis or treatment delay-related
mortality was not within the scope of this study.
Because of the small number of events despite
compiling 12 years of icABAD patients, visceral ischemia
cases were pooled and compared with cases with lower
extremity ischemia only. Survival in patients with visceral
ischemia was not signiﬁcantly associated with decreased
survival vs patients suffering lower extremity ischemia
alone, although a trend toward decreased survival was
observed. Previous studies have identiﬁed visceral ischemia
as an independent predictor of perioperative mortality in
open surgical patients,26 but no such delineation between
visceral and lower extremity ischemia has been reported
with multiple studies identifying malperfusion of any
vascular bed as an independent mortality predictor.1,22,27
We, therefore, recommend that any of the aforementioned
signs of malperfusion following blood pressure optimiza-
tion should be aggressively treated.
Identifying factors imparting freedom from reinterven-
tion was the other major objective of this study.
Nonsmokers had a signiﬁcant decrease in the need for rein-
tervention. Increased healing times, hypercoagulability
imparted by cigarette smoke, and a plethora of other effects
that cigarette smoke has on vascular disease are doubtlessly
attributable to this ﬁnding.18 Spinal cord ischemia
at presentation was associated with decreased freedom
from reintervention. One theory is that surgeons are hesi-
tant to extensively cover zone IV of the descending aorta
because of the risk of cutting off collateral ﬂow to the
cord. This shortened coverage could prevent complete
re-expansion of the true lumen, leaving obstruction of
aortic branch vessels as a possibility. In addition, spinal
cord ischemia would be a reason to choose a proximal
landing zone distal to the left subclavian to avoid reducing
collateral ﬂow from the LSA to the spinal column. We
recommend treating the primary entry tear, and angio-
graphic evidence of perfusion to malperfused vascular
beds should be obtained. Care should always be taken to
avoid coverage of T8-L2, as stent graft coverage of this
area has been associated with spinal cord malperfusion.28
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 5 Ryan et al 1289However, in the setting of ischemia, it is more important to
provide adequate ﬂow. Also, to avoid late aortic events, we
are now more inclined to cover more distal aorta if it is
affected by the dissection. Adjunctive use of a spinal drain
set to 10 cm water pressure as well as maintenance of
a mean arterial pressure $70 mm Hg can both be effective
in restoring and maintaining ﬂow to the spinal cord.
Not surprising, branch vessel stenting was also nega-
tively associated with freedom from reintervention. Static
obstruction of aortic branch vessels can persist despite
depressurization of the false lumen and elimination of
dynamic obstruction because of extension of the false
lumen into branch vessel ostia.8 The need to place branch
vessel stents indicates a more severe dissection pathology
that is not amenable to TEVAR alone. Continued signs
of malperfusion relating to the lack of adequate reperfusion
as well as the inherent complexity with placing branching
stents into the diseased true lumen may require a second
operation to extend stenting into branch vessels or extend
the thoracic endograft to eliminate distal perfusion of the
false lumen via reentry tears.
This study is not without limitations. This is a non-
randomized, single-center, retrospective study that cannot
draw ﬁrm, evidence-based conclusions about TEVAR vs
other therapies. In addition, exact entry site determination
could not be made for all patients, which precluded prox-
imal entry tear site in reference to the LSA from being
analyzed as a predictor of survival. The length of aorta
covered by implanted grafts was also not measured in this
cohort, and both of these variables will be topics for a future
study. Finally, whereas our study encompasses the major
cohort of symptomatic type B dissections, despite 12 years’
experience treating icABAD patients with TEVAR, our
sample size of 61 patients was too small for meaningful
multivariate analyses to be performed. However, this is to
our knowledge, one of the largest single-center cohorts
of icABAD patients treated using TEVAR and stent graft-
ing reported in the literature.
In conclusion, TEVAR is an effective and safe mode
for treating icABAD. A review of IRAD data speciﬁcally
targeting malperfusion may be beneﬁcial in elucidating
more predictors of morbidity, mortality, and freedom
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for you. There is a pretty high complication rate of renal failure.
Were most of these patients who came in with renal ischemia as
well, or was this secondary to the procedure?
Dr Timur P. Sarac (Cleveland, Ohio). Most of the patients
who came in with a dissection ﬂap obstructing the renal arteries
with acute renal failure. All the patients in this cohort received
a stent graft for it. We had three patients who we subsequently
reanalyzed and went back and looked at all of our visceral stenting,
and only three patients which were not included in this actually
had stenting of the visceral vessels that we did not put in a thoracic
stent graft. So, our bias is to treat the dissections with the stent
graft and exclude the entry tear and expand the true lumen as
much as possible. Adjunctive stenting of the branch vessel was
necessary in 25% of the patients.
Dr Firas Mussa (New York, NY ). Could you predict why did
those who had left subclavian coverage ended up with a worse
outcome?
Dr Sarac. There is one patient in this series who we covered
the subclavian artery who had a retrograde dissection who expired.
There is no way for me to tell you exactly what the reason is other
than to say that it really is an indication of the extent of the disease,
which acts as a metric for the patients overall condition as these
patients have very diseased aortas and branch vessels.
Dr Richard Cambria (Boston, Mass). Tim, I wanted to ask
a question about how you deﬁned your patient population. I agree
with your conclusion that 20% mortality at 30 days is acceptable in
these patients. When we ﬁrst presented such a series 25 years ago at
this meeting, the mortality for visceral ischemia complicating
dissection was 80%. But my question relates to how you deﬁne
visceral ischemia. Were these radiographic deﬁnitions? Were they
clinically manifest visceral ischemia? And what did the patients
die from?
At 20%, the 30-day mortality is a little higher than the Society
of Vascular Surgery Outcomes Committee objective performance
criteria paper, which had 10% 30-day mortality. So your thoughts
on how the patients might differ.
Dr Sarac. All of the patients all presented with severe symp-
toms of end organ-ischemia. For example, for renal failure, they
were oliguric and had rising creatinine, and for visceral involve-
ment, their lactates were very high, and they had abdominal
pain. So, all these patients truly had emergent operative
indications.
If you look at the number of patients in this group that were
treated within 24 hours of presentation, it was more than one-half
of them. Three of the patients actually underwent dialysis in the
operating room. I think that may have been the difference in
patient population between the two.
Looking at the International Registry of Acute Aortic Dissec-
tions (IRAD) registry, of which there are several excellent reports
out, even in the past 4 months, the cohort of mesenteric patientsand the mortality rate can be as high as 64% in one subsequent
post hoc analysis.
Dr Jean-Paul de Vries (Nieuwegein, The Netherlands). I
want to focus on spinal cord ischemia. Can you give details,
what percentage of the patients have acute spinal cord ischemia
and what percentage suffer from delayed spinal cord ischemia?
And what is your protocol? Does it include cerebrospinal ﬂuid
drainage? Motor-evoked potential and spinal-evoked potential
monitoring?
Dr Sarac. The overall spinal cord ischemia rate was 11.3%. If
the time will allow during the patient’s clinical presentation, we
will get a spinal drain in. That happened in less than one-half of
these patients. Postop all the patients are monitored closely, and
we tend to keep the mean arterial pressure much higher than we
normally would. And this is a high complication rate of 10% or
11% for spinal cord ischemia. One-half of those were paraparesis
that recovered and half of them went on to infarction.
Dr John Ricotta (Washington, DC). Tim, as I saw it, you had
a very high reintervention rate, which certainly has been the expe-
rience of a lot of people including our own experience. How do
you follow these patients?
One of the Achilles’ heels of this whole problem is that the
false lumen does not thrombose in most of the patients. They still
have a diseased aorta, and they do not necessarily get very good
follow-up either for the management of their hypertension or for
late complications, which occurred in about one-half of your
patients. Could you comment about what your protocol is and
how you think we could improve our care paths in that regard.
Dr Sarac. All the patients get a computerized axial tomog-
raphy scan before they leave the intensive care unit, particularly
the ones who have a spinal drain in. They are all seen again at 1
month and then 6 months, every 6 months for the ﬁrst couple
of years.
The point of hypertension control is a big deal. And the reason
I say that is that in most of the patients, as with most of the tertiary
and quaternary places that are doing thoracic endovascular aortic
repair for dissections, it is difﬁcult to manage their hypertension
as surgeons and getting their primary care doctors involved is
important. Certainly, the patients in our institute initially get
admitted to the cardiology unit, and they do a great job of getting
the hypertension under control. But postoperatively, that is a big
deal and we have a big concern for following these patients and
maybe we ought to be doing more for that.
One of the things that we have adopted, and I think more
anecdotal evidence, but Dan and I were talking about the length
and what length of aorta we cover. And I think our bias now is
to cover as much of this as we can. I am interested to see about
the long-term results of the recently reported Petticoat trial, if
that will make a difference when we use a bare-metal stent in the
distal aorta area. But, we do tend to cover as far as we can all
the way down to the celiac artery.
